Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
about
Current approaches in treatment of triple-negative breast cancerMicroRNAs and triple negative breast cancerSystemic treatment strategies for triple-negative breast cancer.Novel therapeutic strategies for patients with triple-negative breast cancerAngiogenesis and Antiangiogenesis in Triple-Negative Breast cancerClinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trialsPhase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancerTriple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsTriple-negative breast cancer: new perspectives for targeted therapies.Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.Triple-negative breast cancer: an update on neoadjuvant clinical trials.Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer.Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled TrialsA pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-AnalysisTime-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies.Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.Update on triple-negative breast cancer: prognosis and management strategiesThe value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.Triple-negative breast cancer: investigating potential molecular therapeutic target.Bevacizumab: a review of its use in advanced cancer.Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.Resistance to Targeted Therapies in Breast Cancer.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease.Antiangiogenic therapy in breast cancer.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.Clinical and Molecular Methods in Drug Development: Neoadjuvant Systemic Therapy in Breast Cancer as a Model.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPrecision medicine based on tumorigenic signaling pathways for triple-negative breast cancer
P2860
Q26801549-D6C68A45-4E13-4DC9-93D9-7129F445DE3AQ26862716-15C309FC-628B-4E61-AB4F-3E90A5F27E83Q27691414-5F4D11D5-3D57-4C31-A875-47C82FF583DEQ28067436-261D26AE-9C42-4FCF-A48D-870AF09260F1Q28079013-382D59D1-8B48-4C37-8E39-C885AF4B40DDQ31157714-58A44845-2B8F-453E-83FF-4B7602A98C32Q33438050-E7411713-0BDC-4E22-BF1E-3FE6A8604CD6Q33922971-A63F692C-5395-4706-B80B-1A5BBE719E1DQ34646376-D5DEAD39-93BD-4C4B-B007-4F89F4AF3C2EQ35001758-4A0D3550-55F2-4542-98A5-FCAF29480382Q35576250-038F080E-24D8-411C-A5DD-FCABECCDDD01Q35689902-AA9AB061-FEC9-4599-BC6D-53C8ED20E539Q35725961-0D7911B9-4B6A-4E2C-BDDB-8B5B3AB609B7Q35789399-CCE5E3D9-C809-48E4-8ACA-99C2587556AFQ35789457-C73E3320-1846-4C33-83A3-8DFB7784633BQ35881780-50BC0BF0-A7F1-400C-B8B5-B639BDBB85B2Q36076814-D9FE5B7B-724D-4280-AD33-ED8D27CF1051Q36118278-DB50FCB8-FBA0-4FB2-A563-3D734C09E6CFQ36216452-B966C146-6301-4612-88FA-B8B5DCDE6EBCQ36219254-6D92E554-D3D7-4120-9A06-6B6C6B482282Q36311616-E5D07AF4-4564-45F3-BF34-6AE4EB81A799Q38190005-BB6F892D-8420-49CC-A609-391E48613F3CQ38259322-A7FEC720-04D8-49D3-A823-7CF4A240E502Q38260176-13D147E9-6B4C-4445-90AE-769082F9F5D3Q38440214-E3E4A9B5-024C-4B8F-8392-832672328C99Q38647802-91F8773A-D516-4186-BF55-DCF229729960Q38677841-9F56F226-E9F1-4D1F-A42F-0FAC898D8E8EQ38748114-3944014D-89C4-4BED-987E-8E44F13EF5F6Q39375196-BDB0591F-EEE0-463F-92EC-59F38E7C0321Q45047438-4ACA4DA1-B8E4-4B37-B32C-E51FE8C1976AQ46894943-3580E35C-A400-4781-9992-FE747B5D5C81Q47111400-A294F36B-6167-470B-B66A-6E1EFECE01C6Q47121796-149F5641-D086-47D9-9AB3-A83D680B5D77Q47260496-F77E55F2-1E39-4F34-A740-29D11B4EBC66Q48444536-05243D96-4F81-4B34-897D-417DD361627FQ49303842-CAFC22FE-BFCA-42F6-B4D9-F7A3174D19D2Q52984715-FE561838-62D9-4D65-B791-0D3E416FB622Q55428234-5CFDF28E-8051-4BE3-936B-2C670C2E170BQ56968709-FFFF75D5-B37F-4F75-A687-9C0F2B255CFEQ57105411-4B5A5A09-2EFB-4819-A868-4CFCB8696A7D
P2860
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Neoadjuvant bevacizumab and an ...... he geparquinto study (GBG 44).
@en
Neoadjuvant bevacizumab and an ...... lts from the geparquinto study
@nl
type
label
Neoadjuvant bevacizumab and an ...... he geparquinto study (GBG 44).
@en
Neoadjuvant bevacizumab and an ...... lts from the geparquinto study
@nl
prefLabel
Neoadjuvant bevacizumab and an ...... he geparquinto study (GBG 44).
@en
Neoadjuvant bevacizumab and an ...... lts from the geparquinto study
@nl
P2093
P2860
P50
P356
P1433
P1476
Neoadjuvant bevacizumab and an ...... he geparquinto study (GBG 44).
@en
P2093
C Jackisch
G von Minckwitz
German Breast Group Investigators
H Eggemann
H Eidtmann
P2860
P304
P356
10.1093/ANNONC/MDT361
P577
2013-10-17T00:00:00Z